Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide

• Autor(a) principal: Alemany, Laia
• Data de Publicação: 2015
• Outros Autores: Saunier, Maëlle, Alvarado-Cabrero, Isabel, Quirõs, Beatriz, Salmeron, Jorge, Shin, Hai Rim, Pirog, Edyta C., Guimerà, Núria, Hernandez-Suarez, Gustavo, Felix, Ana, Clavero, Omar, Lloveras, Belen, Kasamatsu, Elena, Goodman, Marc T., Hernandez, Brenda Y., Laco, Jan, Tinoco, Leopoldo, Geraets, Daan T., Lynch, Charles F., Mandys, Vaclav, Poljak, Mario, Jach, Robert, Verge, Josep, Clavel, Christine, Ndiaye, Cathy, Klaustermeier, Joellen, Cubilla, Antonio, Castellsagué, Xavier, Bravo, Ignacio G., Pawlita, Michael, Quint, William G., Muñoz, Nubia, Bosch, Francesc X., De Sanjosé, Silvia
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/152631
• topic: anal cancer; human papillomavirus; vaccine; Oncology; Cancer Research; SDG 3 - Good Health and Well-being

Knowledge about human papillomaviruses (HPV) types involved in anal cancers in some world regions is scanty. Here, we describe the HPV DNA prevalence and type distribution in a series of invasive anal cancers and anal intraepithelial neoplasias (AIN) grades 2/3 from 24 countries. We analyzed 43 AIN 2/3 cases and 496 anal cancers diagnosed from 1986 to 2011. After histopathological evaluation of formalin-fixed paraffin-embedded samples, HPV DNA detection and genotyping was performed using SPF-10/DEIA/LiPA25 system (version 1). A subset of 116 cancers was further tested for p16INK4a expression, a cellular surrogate marker for HPV-associated transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance in the anal cancer data set. HPV DNA was detected in 88.3% of anal cancers (95% confidence interval [CI]: 85.1-91.0%) and in 95.3% of AIN 2/3 (95% CI: 84.2-99.4%). Among cancers, the highest prevalence was observed in warty-basaloid subtype of squamous cell carcinomas, in younger patients and in North American geographical region. There were no statistically significant differences in prevalence by gender. HPV16 was the most frequent HPV type detected in both cancers (80.7%) and AIN 2/3 lesions (75.4%). HPV18 was the second most common type in invasive cancers (3.6%). p16INK4a overexpression was found in 95% of HPV DNA-positive anal cancers. In view of the results of HPV DNA and high proportion of p16INK4a overexpression, infection by HPV is most likely to be a necessary cause for anal cancers in both men and women. The large contribution of HPV16 reinforces the potential impact of HPV vaccines in the prevention of these lesions. What's new? Human papillomavirus (HPV) is linked to anal cancer through high HPV DNA-detection rates. Here, in one of the largest international studies to date, HPV DNA was detected in more than 88% of anal cancers and more than 95% of anal intraepithelial neoplasias grades 2/3. HPV16 was the most frequently detected virus type, followed by HPV18. Overexpression of p16INK4a, a surrogate marker for HPV-associated transformation, was found in 95% of HPV-positive anal cancers. The data implicate HPV as a causative factor in anal cancer.